| [1] | Hanahan, D., and Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell 144 : 646−674. DOI: 10.1016/j.cell.2011.02.013. |
| [2] | Hong, D.S., Fakih, M.G., Strickler, J.H., et al. (2020). KRASG12C inhibition with sotorasib in advanced solid tumors. N. Engl. J. Med. 383 : 1207−1217. DOI: 10.1056/NEJMoa1917239. |
| [3] | Zeidan, A.M., Al-Kali, A., Borate, U., et al. (2021). Sabatolimab (MBG453) combination treatment regimens for patients (Pts) with higher-risk myelodysplastic syndromes (HR-MDS): the MDS studies in the stimulus immuno-myeloid clinical trial program. Blood 138 (Supplement 1) : 4669. DOI: 10.1182/blood-2021-145626. |
| [4] | Tsurutani, J., Iwata, H., Krop, I., et al. (2020). Targeting HER2 with trastuzumab deruxtecan: a dose-expansion, phase I study in multiple advanced solid tumors. Cancer Discov. 10 : 688−701. DOI: 10.1158/2159-8290.CD-19-1014. |
| [5] | Nathan, P., Hassel, J.C., Rutkowski, P., et al. (2021). Overall survival benefit with tebentafusp in metastatic uveal melanoma. N. Engl. J. Med. 385 : 1196−1206. DOI: 10.1056/NEJMoa2103485. |
| Huang X. and Cao X. (2023). Innovative drugs bring continuous benefits to cancer patients. The Innovation Life 1(3), 100043. https://doi.org/10.59717/j.xinn-life.2023.100043 |
To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.
Representative innovative anticancer drugs at the moment